Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.
MoonLake Immunotherapeutics reports clinical, regulatory and financing developments for a clinical-stage biotechnology business focused on inflammatory skin and joint diseases. Its updates center on sonelokimab (SLK), a Nanobody designed to inhibit IL-17A and IL-17F, and on programs in hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis.
Recurring news includes Phase 2 and Phase 3 trial data from VELA, VELA-TEEN, MIRA, LEDA, S-OLARIS and IZAR studies, FDA interactions and designations tied to SLK, quarterly financial results, research and development spending, equity and debt financing activity, and shareholder voting or capital-structure matters.
MoonLake Immunotherapeutics announced the completion of patient enrollment and randomization ahead of schedule for its Phase 2 clinical trial of sonelokimab in treating moderate-to-severe hidradenitis suppurativa (HS). The trial, known as the MIRA trial, has reached its target of 210 patients and aims to evaluate the effectiveness of sonelokimab, a novel IL-17A and IL-17F inhibitor. Top-line results are expected by mid-2023, with a final readout planned for Q4 2023. The trial uses HiSCR75 as its primary endpoint, reflecting MoonLake's ambition to improve patient outcomes.
MoonLake Immunotherapeutics has initiated a Phase 2 study named ARGO for sonelokimab, targeting active psoriatic arthritis.
The randomized, double-blind trial involves approximately 200 patients to evaluate the drug's efficacy and safety against a placebo and adalimumab.
The primary endpoint is the ACR 50 response, measuring ≥50% improvement in disease symptoms. This follows successful results from a Phase 2b study in psoriasis, highlighting sonelokimab's potential in treating inflammatory conditions.
MoonLake Immunotherapeutics (NASDAQ:MLTX) reported its Q3 2022 financial results, highlighting a cash position of $83.5 million, providing a runway into 2H 2024. The global trial of sonelokimab for Hidradenitis Suppurativa continues to meet recruitment goals, with primary endpoint data expected mid-2023. Additionally, the Psoriatic Arthritis trial received FDA clearance and is on schedule. R&D expenses decreased to $9 million from $11.4 million, while the net loss narrowed to $14.7 million compared to the previous quarter.
MoonLake Immunotherapeutics has received FDA clearance to initiate a global Phase 2 clinical study for its investigational Nanobody® sonelokimab in patients with active psoriatic arthritis. The study aims to enroll around 200 patients to evaluate the drug's efficacy and safety against a placebo, with adalimumab as a reference. This milestone follows the completion of prior clinical trials and aims to assess significant outcomes related to this complex disease.
MoonLake Immunotherapeutics has signed a Master Development Services Agreement with Vetter Pharma International. This partnership will focus on the aseptic filling of syringes with sonelokimab, an investigational Nanobody® targeting inflammatory diseases. The manufacturing studies are set to conclude, with clinical Good Manufacturing Practice batches expected by Q4 2022. This agreement strengthens the supply chain for sonelokimab, aimed at conditions like hidradenitis suppurativa and psoriatic arthritis, significantly impacting patients in need.
MoonLake Immunotherapeutics has commenced a Phase 2 clinical trial for sonelokimab, a novel Nanobody® aimed at treating moderate-to-severe hidradenitis suppurativa (HS). This trial is significant as it uses the HiSCR75 endpoint, a ≥75% reduction in total abscess and inflammatory nodule count. The global trial will include over 200 patients, comparing sonelokimab to placebo and adalimumab. This milestone follows the FDA's approval of the trial protocol, with expected completion by the end of 2023. Sonelokimab targets IL-17 dimers, potentially improving outcomes for HS patients.